These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 1732048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, Noe DA, Grochow LB.
    Cancer Res; 1990 Jun 01; 50(11):3284-8. PubMed ID: 2334921
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase I and clinical pharmacological evaluation of pirozantrone hydrochloride (oxantrazole).
    Ames MM, Loprinzi CL, Collins JM, van Haelst-Pisani C, Richardson RL, Rubin J, Moertel CG.
    Cancer Res; 1990 Jul 01; 50(13):3905-9. PubMed ID: 2191768
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1.
    Foster BJ, Wiegand RA, LoRusso PM, Baker LH.
    Clin Cancer Res; 1995 Aug 01; 1(8):831-7. PubMed ID: 9816052
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
    Cancer Chemother Pharmacol; 2004 Sep 01; 54(3):206-12. PubMed ID: 15156345
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of the anthrapyrazole CI-941: prospective evaluation of a pharmacokinetically guided dose-escalation.
    Foster BJ, Newell DR, Graham MA, Gumbrell LA, Jenns KE, Kaye SB, Calvert AH.
    Eur J Cancer; 1992 Sep 01; 28(2-3):463-9. PubMed ID: 1591064
    [Abstract] [Full Text] [Related]

  • 11. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.
    Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR.
    Clin Cancer Res; 1995 Dec 01; 1(12):1479-86. PubMed ID: 9815947
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of piroxantrone in a phase I trial of piroxantrone and granulocyte-colony stimulating factor.
    Berg SL, Savarese DM, Balis FM, Denicoff AM, Hillig M, O'Shaughnessy JA, Poplack DG, Cowan KH.
    Cancer Res; 1993 Jun 01; 53(11):2587-90. PubMed ID: 7684320
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA, Senan S, Robin H, Eckhardt N, Lendrem D, Hincks J, Greenslade D, Rampling R, Kaye SB, von Roemeling R, Workman P.
    Cancer Chemother Pharmacol; 1997 Jun 01; 40(1):1-10. PubMed ID: 9137522
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E.
    Clin Cancer Res; 2000 Apr 01; 6(4):1205-18. PubMed ID: 10778943
    [Abstract] [Full Text] [Related]

  • 15. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG, Balcerzak SP, Kraut EH.
    Cancer Res; 1993 Oct 15; 53(20):4843-9. PubMed ID: 8402671
    [Abstract] [Full Text] [Related]

  • 16. Lack of dose proportional pharmacokinetics for CI-937, an anthrapyrazole DNA intercalator, in mice.
    Wong B, Nordblom G, Chang T, Whitfield L.
    Res Commun Chem Pathol Pharmacol; 1989 Nov 15; 66(2):191-202. PubMed ID: 2602655
    [Abstract] [Full Text] [Related]

  • 17. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ.
    Cancer Res; 1994 Jan 01; 54(1):114-9. PubMed ID: 8261430
    [Abstract] [Full Text] [Related]

  • 18. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA, Bissett D, Setanoians A, Hamilton T, Kerr DJ, Henrar R, Kaye SB.
    J Natl Cancer Inst; 1992 Apr 01; 84(7):494-500. PubMed ID: 1545439
    [Abstract] [Full Text] [Related]

  • 19. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

  • 20. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A, Scheulen ME, Schmoll HJ, Gründel O, Harstrick A, Knoche M, Fels LM, Skorzec M, Bach F, Baumgart J, Sass G, Seeber S, Thiel E, Berdel WE.
    Clin Cancer Res; 1998 Nov 15; 4(11):2701-8. PubMed ID: 9829732
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.